What is the appropriate treatment regimen for genital herpes simplex?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Genital Herpes Simplex Treatment

For first-episode genital herpes, treat with valaciclovir 500 mg orally twice daily for 10 days, or aciclovir 400 mg orally three times daily for 10 days; for recurrent episodes, use shorter courses (valaciclovir 500 mg twice daily for 3 days or aciclovir 800 mg three times daily for 2 days), and offer daily suppressive therapy to patients with frequent recurrences (≥6 episodes/year) or those wishing to reduce transmission risk. 1

Treatment Approach: Three Clinical Scenarios

1. First Clinical Episode (Primary Infection)

The initial outbreak typically presents with painful, erythematous vesicular or ulcerative lesions and warrants the longest treatment duration:

  • Valaciclovir 500 mg orally twice daily for 10 days (preferred for convenience) 1
  • Aciclovir 400 mg orally three times daily for 10 days (alternative, equally effective) 1
  • Aciclovir 200 mg orally five times daily for 10 days is also effective but less convenient 1

The 10-day duration is critical for first episodes because it reduces viral replication, symptom severity, and duration more effectively than shorter courses 1. Treatment should begin immediately when lesions are present—do not wait for laboratory confirmation if clinical suspicion is high.

2. Recurrent Episodes (Episodic Therapy)

For patients with infrequent recurrences who prefer treatment only during outbreaks, use shorter, more convenient regimens:

  • Valaciclovir 500 mg orally twice daily for 3 days (most convenient) 1
  • Aciclovir 800 mg orally three times daily for 2 days (ultra-short course) 1
  • Aciclovir 400 mg orally three times daily for 5 days (alternative) 1

These abbreviated courses are effective because recurrent episodes involve less viral replication than primary infection. Patients should initiate therapy at the first sign of prodromal symptoms (tingling, burning) or lesion appearance for maximum benefit.

3. Suppressive Therapy (Daily Prevention)

Offer suppressive therapy to patients with:

  • Frequent recurrences (≥6 episodes per year)
  • Significant psychological distress from recurrences
  • Desire to reduce transmission to serodiscordant partners
  • Immunocompromised status

Regimens:

  • Valaciclovir 500 mg orally once daily (most convenient, only once-daily option) 1, 2
  • Aciclovir 400 mg orally twice daily (alternative) 1

Suppressive therapy reduces symptomatic outbreaks by 70-80% and significantly decreases asymptomatic viral shedding, which is the primary mode of transmission 3, 4. The once-daily valaciclovir regimen improves adherence compared to twice-daily dosing.

Diagnostic Confirmation

When lesions are present, obtain a swab for PCR testing—this is the gold standard with superior sensitivity over viral culture 1. PCR can detect HSV even from healing lesions where culture often fails. Type-specific serology (Western blot) identifies previous exposure but does not diagnose active infection and should not be used for routine screening in asymptomatic individuals due to high prevalence and psychological burden 1.

Special Populations

Pregnancy

  • First episode during pregnancy: Treat with aciclovir 400 mg three times daily or valaciclovir 500 mg twice daily for 5-10 days depending on severity 5
  • Suppressive prophylaxis after 36 weeks: Aciclovir 400 mg three times daily or valaciclovir 500 mg twice daily until delivery to reduce cesarean section risk from active lesions at delivery 5

Aciclovir has more extensive safety data in pregnancy, though valaciclovir is also considered safe 5.

Immunocompromised Patients

Consider longer treatment courses and lower threshold for suppressive therapy, as these patients experience more severe and prolonged outbreaks 6, 7.

Common Pitfalls to Avoid

Do not use topical antivirals as primary therapy—they show minimal clinical benefit compared to oral agents 1. Topical aciclovir and tenofovir have limited efficacy for genital herpes.

Do not routinely screen asymptomatic individuals with serology—this creates psychological burden without clear clinical benefit given the high population prevalence 1.

Do not delay treatment waiting for test results if clinical presentation is classic—early initiation (within 72 hours of symptom onset) provides maximum benefit.

Recognize that 27-48% of patients experience recurrence within the first year after initial outbreak 1—counsel patients about this likelihood and provide clear instructions for episodic or suppressive therapy options.

Emerging Therapies

Novel agents like pritelivir and amenamevir are under investigation with potential advantages in dosing and resistance profiles, but nucleoside analogs (aciclovir/valaciclovir) remain first-line therapy 1. No vaccine has demonstrated clinical efficacy to date 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.